Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension.

Pulmonary circulation·2026
Same author

CES1 links lipid dysregulation and endothelial pathology in pulmonary arterial hypertension.

American journal of respiratory and critical care medicine·2026
Same author

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management.

Pulmonary circulation·2026
Same author

Endothelial <i>GATA6</i> deficiency suppresses intracellular TLR3-interferon signaling in HPAECs and promotes interferon response in HPASMCs.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jul 14, 2026

A Murine Tail Lymphedema Model
04:38

A Murine Tail Lymphedema Model

Published on: February 10, 2021

Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.

Elena A Goncharova1, Vera P Krymskaya

  • 1Department of Medicine, University of Pennsylvania, Pennsylvania, USA.

Journal of Cellular Biochemistry
|June 2, 2007
PubMed
Summary

Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by mutations in TSC1 or TSC2 genes, affecting smooth muscle cells. Understanding its molecular mechanisms may offer insights into metabolic diseases like diabetes and cancer.

More Related Videos

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice
09:50

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Related Experiment Videos

Last Updated: Jul 14, 2026

A Murine Tail Lymphedema Model
04:38

A Murine Tail Lymphedema Model

Published on: February 10, 2021

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice
09:50

A Revised Method for Inducing Secondary Lymphedema in the Hindlimb of Mice

Published on: November 2, 2019

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Genetics

Background:

  • Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease primarily affecting women.
  • LAM involves the abnormal proliferation of smooth muscle-like cells, leading to lung destruction and respiratory failure.
  • Current treatment options are limited, with lung transplantation being the only life-saving intervention.

Purpose of the Study:

  • To review the current understanding of tuberous sclerosis complex 1 (TSC1) and TSC2 (TSC1/TSC2) cellular signaling in LAM.
  • To explore the molecular mechanisms underlying LAM pathogenesis.
  • To highlight emerging research directions and challenges in LAM investigation.

Main Methods:

  • Literature review of studies on LAM, TSC1/TSC2 signaling, and mTOR/S6K1 pathway.
  • Analysis of genetic and somatic mutations in LAM patients.
  • Synthesis of current knowledge on LAM molecular biology and potential therapeutic targets.

Main Results:

  • Mutations in TSC1 or TSC2 genes are identified as key drivers of LAM.
  • The TSC1/TSC2 protein complex negatively regulates the mTOR/S6K1 signaling pathway, crucial in LAM development.
  • The TSC1/TSC2 complex integrates signals from growth factors, insulin, nutrients, and energy, linking LAM to broader metabolic pathways.

Conclusions:

  • Elucidating TSC1/TSC2 signaling in LAM provides insights into the disease's molecular basis.
  • Understanding LAM mechanisms can advance knowledge of other metabolic diseases, including diabetes, cancer, and cardiovascular conditions.
  • Further research into TSC1/TSC2 signaling and LAM pathogenesis is crucial for developing novel therapeutic strategies.